Breaking News

Financial Report: Amgen

By Kristin Brooks | January 29, 2014

Product sales up 11% in the quarter


4Q Revenues: $5.0 billion (+13%)

4Q Earnings: $1.0 billion (+30%)

FY Revenues: $18.7 billion (+8%)

FY Earnings: $5.1 billion (+17%)

Comments: Total product sales increased 11% in the quarter to $4.8 billion. Combined Neulastaand NEUPOGEN sales were up 8% in the quarter to $1.4 billion. Enbrel sales were up 3% to $1.2 billion. Aranesp sales decreased 4% to $470 million in the quarter, due to lower demand. EPOGEN sales increased 10% to $525 million. Sensipar/Mimparasales increased 20% to $307 million. XGEVA/ Prolia sales increased 41% to $522 million. R&D expenses were up 27% in the quarter to $1.2 billion. The fourth quarter includes results for Onyx Pharmaceuticals, acquired in October 2013.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks